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complications	(DM+C) present with a more severe clinical profile and if that relates to 
increased	mortality,	compared	to	those	with	diabetes	with	no	complications	(DM-	NC)	
and those without diabetes.
Methods: Service-	level	 data	was	 used	 from	 996	 adults	with	 laboratory	 confirmed	
COVID-	19	who	 presented	 to	 the	Queen	 Elizabeth	Hospital	 Birmingham,	UK,	 from	
March	to	June	2020.	All	individuals	were	categorized	into	DM+C,	DM-	NC,	and	non-	
diabetes	groups.	Physiological	and	laboratory	measurements	in	the	first	5	days	after	
admission were collated and compared among groups. Cox proportional hazards re-









HRs	were	1.39	(95%	CI	0.95–	2.03,	p =	0.093)	and	1.18	(95%	CI	0.90–	1.54,	p = 0.226) 
in	DM+C	and	DM-	C,	respectively.
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1  |  INTRODUC TION
Coronavirus	 disease	 2019	 (COVID-	19)	 has	 impacted	 on	morbidity	
and	mortality	of	people	across	the	globe.	People	with	diabetes	mel-

















for initial clinical status or severity on initial admission to hospitals.2 
A	novel	approach	could	be	 to	examine	service	 level	hospital	data,	
including	blood	 tests	and	other	measures,	which	clinicians	use	 for	
initial patient assessment and progress. The results may aid strate-
gies	for	early	clinical	risk	stratification	for	treatment	or	alternatively,	
guide prevention strategies (eg vaccinations).
The	aim	of	this	study	is	to	examine	whether	DM+C patients with 
COVID-	19	present	with	more	adverse	clinical	and	biochemical	pro-
files	 and	 increased	mortality	 compared	 to	 people	with	 COVID-	19	
and	DM-	NC	or	without	DM	in	an	extensively	phenotype	adult	co-
hort presenting to a large urban UK hospital.
2  |  METHODS
2.1  |  Study setting
This	retrospective	cohort	study,	using	prospectively	collected	data,	
was	conducted	in	Queen	Elizabeth	Hospital	Birmingham	(QEHB),	a	
large teaching hospital within University Hospitals of Birmingham 
(UHB).	 It	 is	situated	in	the	city	of	Birmingham,	West	Midlands,	UK	
and	 has	 over	 1200	 beds.	West	 Midlands	 is	 a	 multi-	ethnic	 region	
with	30%	of	residents	classified	as	Black,	Asian	and	Minority	Ethnic	
(BAME),	 of	whom	South	Asians	 (18.9%)	 and	Blacks	 (6.0%)	 are	 the	




internal medicine teams and cases were escalated to intensive care 
units for mechanical ventilation as per clinician judgement. Those 
with	COVID-	19	and	DM	were	assessed	by	a	specialist	diabetes	team	
as needed. This study is reported as per the Reporting of studies 
Conducted	 using	 Observational	 Routinely-	collected	 health	 Data	
(RECORD)	Statement.6
2.2  |  Data sources
We	constructed	the	data	using	the	Patient	Administration	Database	
(PAS)	 and	 the	 Electronic	 Medical	 Record	 system,	 known	 as	 the	
Patient	Information	and	Communication	System	(PICS).	The	PAS	da-
tabase	 record	 information	on	age,	 gender,	 ethnicity,	 address	 (post	
code),	 primary	 reason	 for	 admission,	 discharge	 diagnostic	 codes,	
inpatient	death,	and	discharge	destination.	Admission	is	defined	as	
the time spent by an individual from recorded time of entry to re-
corded	time	of	exit	from	the	hospital.	The	PAS	database	was	linked	
using	unique	patient	 identifiers	 (hospital	number)	to	the	PICS.	 It	 is	
a	 purpose-	designed	 system	which	 records	 all	 in-	hospital	 prescrip-
tions,	laboratory	results	and	electronic	observations	and	generates	
alerts to reduce prescription errors and notify abnormal blood re-
sults.7	The	linked	PAS-	PICS	databases	have	been	used	for	multiple	
diabetes related research.8-	10




2.4  |  Data collection and variable definitions
Patient	demographics	and	clinical	data	were	collected	from	PAS	and	
PICS.	Clinician	confirmed	co-	morbidities	were	available	from	PAS	and	









Conclusions: Those	with	COVID-	19	and	DM+C presented with a more severe clini-
cal	and	biochemical	profile,	but	this	did	not	associate	with	increased	mortality	in	this	
study.
K E Y W O R D S
complications,	COVID-	19,	diabetes
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chaemic attack and ischaemic heart disease.
2.5  |  Clinical assessments
All	 patients	 underwent	 nasopharyngeal	 and	 oropharyngeal	 swab	
specimen	 (miniature	 absorbent	 pads)	 testing	 for	COVID-	19.	 These	
were	processed	in	accordance	with	NHS	guidance	within	UHB	NHS	
laboratories.11	The	swab	specimens	were	measured	 for	COVID-	19	
using	 either	 real-	time	 reverse	 transcription	 polymerase	 chain	 re-
action or transcription mediated amplification methods on one 
of	 three	 assays:	Abbott	M2000,	Cepheid	GeneXpert	 or	 a	Hologic	
Panther.	Co-	efficient	of	variation	values	were	based	on	calibrations	
and therefore varied between individual runs.
Venepuncture	was	conducted	to	ascertain	venous	blood	for	rou-




included measurement of respiratory rate and pulse rate via a pulse 
auxometer,	systolic	and	diastolic	blood	pressures	and	temperature.	
All	swab	specimens,	blood	tests	and	physiological	assessments	were	
performed by trained healthcare professionals following standard 
operating procedures.
All	physiological	and	laboratory	measurements	were	categorized	
based on clinically meaningful thresholds and the earliest available 
measurement	was	used	in	the	analysis.	Missing	data	were	presented	
as a missing category for all measurements.









Based	 on	 the	 DM	 and	 complications	 status,	 patients	 were	 cat-
egorized	 into	 three	groups:	 (1)	people	with	DM	and	microvascular	




on	 admission	 to	 hospital.	 Body	mass	 index	 (BMI)	was	 categorized	
based	 on	 the	World	 Health	 Organisation	 Criteria:	 normal	 weight	
(BMI	of	< 25 kg/m2),	overweight	(BMI	of	25	kg/m2 to < 30 kg/m2),	
obesity	 (BMI	of	30	kg/m2 to < 35 kg/m2),	 obesity	 II	&	 III	 (BMI	of	




the trends of available physiological and laboratory measurements 
in the first 5 days after admission. These included measures of met-
abolic	 acidosis	 and	 compensation	 (anion	 gap,	 partial	 pressure	 of	
carbon	 dioxide	 (pCO2),	 bicarbonate	 (HCO3-	)	 and	 hydrogen	 ions),	
indicators	of	underlying	presence	of	inflammation	(serum	C-	reactive	
protein,	 CRP),	measures	 of	 immune	 response	 (lymphocyte	 count),	





SE)	 or	median	 (IQR)	 for	 symmetrical	 and	 skewed	 continuous	 vari-
ables,	respectively.





2.9  |  Statistical analyses
Baseline	characteristics	for	the	total	population	and	DM	sub-	groups	







2.10  |  Regression analysis




categories (model comprised the interaction effect between age and 
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CCI	categories).	Missing	data	 for	BMI	and	ethnicity	were	 included	
in	 the	 Cox	model	 as	 a	missing	 category.	 All	 statistical	 tests	 were	




3.1  |  Baseline characteristics





to	 people	 without	 diabetes,	 people	 with	 DM+C	 or	 DM-	NC	were	
more	 likely	 to	 be	 men,	 from	 South	 Asian	 background	 and	 have	
obesity.	People	with	DM+C	had	 the	highest	 levels	of	obesity,	CCI	
score	≥3,	CVD,	 ischaemic	 heart	 disease,	 stroke/TIA,	 heart	 failure,	
hypertension	 and	 end-	stage	 renal	 disease	 (ESRD).	 Levels	 of	 other	
co-	morbidities,	 including	dementia,	cancer,	COPD,	asthma	and	AF,	
did	not	vary	between	the	three	sub-	groups.
3.2  |  Physiological and laboratory measurements 
at presentation and in the first 5 days
Individuals	 with	 DM+C were more likely to present with a pH 
level <	 7.3	 and	 a	 higher	 anion	 gap	 than	 in	 those	with	DM-	NC	 or	
those	without	DM,	p = .001 and p < .001 respectively (Table 2). 
Features	of	renal	impairment	(high	urea,	raised	K+	and	lower	eGFR)	
were	more	common	at	presentation	in	the	DM+C group than in the 
DM-	NC	group	or	those	without	DM,	which	could	be	related	to	un-
derlying	 CKD,	 dehydration	 or	 acute	 kidney	 injury	 associated	with	
acute	COVID-	19.	In	particular,	eGFR	< 30ml/min/1.73m2 was more 
common	 in	 people	 with	 DM+C	 (54.8%)	 than	 those	 with	 DM-	NC	
(18.6%)	and	those	without	DM	(12.9%),	p <	.001.	People	with	DM+C 
also had lower serum albumin and lymphocyte count.
People	with	DM+C	had	lower	levels	of	serum	CRP,	heart	rate	or	











95%	CI	 0.95,	 2.03)	 and	 in	 those	with	DM-	NC	 (1.18,	 95%	CI	 0.90,	
1.54)	compared	to	patients	without	diabetes.	However,	these	find-
ings	 did	 not	 reach	 statistical	 significance,	 p-	values	 of	 0.093	 and	
0.226 respectively.
4  |  DISCUSSION
Our	 study	 shows	 that	 people	 admitted	 with	 symptomatic	
COVID-	19	 and	 DM	 were	 more	 likely	 to	 be	 men,	 from	 a	 BAME	
background,	and	had	higher	BMI	and	more	CVD,	and	more	ESRD	
compared	to	those	without	DM.	In	addition,	patients	with	DM+C 
had	 higher	 BMI,	 CVD	 and	more	 ESRD	 compared	 to	DM-	NC,	 as	
would	have	been	expected.	Patients	with	DM+C had higher anion 
gap,	urea,	potassium,	and	 lower	pH,	 lymphocytes,	albumin,	com-




not	 reach	 significance.	 Other	 predictors	 of	 higher	 mortality	 in-
cluded	age,	higher	CCI,	men	and	BAME	groups.
The	 relatively	 higher	mortality	 observed	 in	 people	 with	 DM	
compared	 to	 those	without	 DM	 in	 this	 study	 is	 consistent	 with	
that	 reported	 previously	 in	 other	 COVID-	19	 studies	 and	 other	
studies	showing	higher	mortality	 in	patients	with	DM	in	relation	
to	 influenza,	SARS	and	MERS.13,14 This increases risk of adverse 
outcomes from these viral infections is likely due to multiple 
mechanisms including impaired immune response within a hy-
perglycaemic environment and reduced cellular expression of 





have been reported previously to be associated with increased risk 




CVD,	CKD	and	mortality	in	DM.17–	19 This is supported by the re-
sults showing differences in heart rate and respiratory rate be-
tween	patients	with	DM+C	and	DM-	NC.	In	addition,	patients	with	
DM+C had biochemical features to suggest more hypovolaemia/ 
dehydration	 on	 admission	 (higher	 urea,	 higher	 anion	 gap	 and	
lower	pH	level),	which	might	be	caused	either	by	having	more	se-
vere infection or the presence of underlying complications such as 
renal	impairment	and	DAN.	However,	these	parameters	remained	
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The results of this study need to be considered in the context 
of its limitations. This study was conducted from a single centre 
which	might	affect	the	external	validity	of	the	findings.	However,	
this	 single	 centre	 is	 a	 large,	 tertiary	 and	 receives	 patients	 form	






Overall Non- diabetes DM- NC DM+C p- value
N 996 597 295 104
Age	(years) 68.4 ± 17.5 68.1 ± 19.0 68.1± 15.2 70.6 ± 13.9 .397
Male 559 (56.1) 314 (52.6) 184 (62.4) 61 (58.7) .019
Ethnicity
White 568 (57.0) 382 (64.0) 140 (47.5) 46 (44.2) <.001
South	Asian 149 (15.0) 60 (10.1) 62 (21.0) 27 (26.0)
Black 63 (6.3) 25 (4.2) 24 (8.1) 14 (13.5)
Others 48 (4.8) 26 (4.4) 18 (6.1) 4 (3.8)
Mixed 11 (1.1) 6 (1.0) 2 (0.7) 3 (2.9)
Missing 157 (15.8) 98 (16.4) 49 (16.6) 10 (9.6)
BMI	(kg/m2) 29.1 ± 7.7 28.0 ± 8.0 30.3 ± 6.9 32.0 ± 7.1 <.001
BMI	categories
<25 282 (28.3) 200 (33.5) 66 (22.4) 16 (15.4) <.001
25 to < 30 327 (32.8) 201 (33.7) 95 (32.2) 31 (29.8)
30 to < 35 182 (18.3) 99 (16.6) 59 (20.0) 24 (23.1)
≥35 172 (17.3) 72 (12.1) 67 (22.7) 33 (31.7)
Missing 33 (3.3) 25 (4.2) 8 (2.7) 0 (0.0)
Charlson	co-	morbidity	index
0 212 (21.3) 145 (24.3) 62 (21.0) 5 (4.8) <.001
1 196 (19.7) 128 (21.4) 62 (21.0) 6 (5.8)
2 131 (13.2) 89 (14.9) 36 (12.2) 6 (5.8)
≥3 457 (45.9) 235 (39.4) 135 (45.8) 87 (83.7)
Cardiovascular 
diseases
431 (43.3) 216 (36.2) 140 (47.5) 75 (72.1) <.001
Ischaemic	heart	
disease
228 (22.9) 99 (16.6) 80 (27.1) 49 (47.1) <.001
Stroke/TIA 78 (7.8) 36 (6.0) 26 (8.8) 16 (15.4) .004
Heart failure 163 (16.4) 77 (12.9) 52 (17.6) 34 (32.7) <.001
Hypertension 628 (63.1) 305 (51.1) 227 (76.9) 96 (92.3) <.001
End-	Stage	Renal	
Disease
100 (10.0) 28 (4.7) 23 (7.8) 49 (47.1) <.001
Dementia 341 (34.2) 203 (34.0) 97 (32.9) 41 (39.4) .473
COPD 260 (26.1) 159 (26.6) 79 (26.8) 22 (21.2) .478
Cancer 125 (12.6) 82 (13.7) 30 (10.2) 13 (12.5) .319
Asthma 153 (15.4) 88 (14.7) 49 (16.6) 16 (15.4) .767
Atrial	Fibrillation 228 (22.9) 130 (21.8) 71 (24.1) 27 (26.0) .547
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TA B L E  2 Baseline	clinical	and	laboratory	test	measurements	according	to	glycaemic	and	complication	status
Non- diabetes DM- NC DM+C p*
N 597 295 104
Anion	Gap	(mmol/l) 19.1 ± 3.2 19.5 ± 3.8 21.7 ± 5.9 <.001
Anion	Gap	categories
6 to < 16 51 (8.5) 27 (9.2) 3 (2.9)
≥16 324 (54.3) 175 (59.3) 57 (54.8) .169
Missing 222 (37.2) 93 (31.5) 44 (42.3)
pCO2	(kPa) 5.5 ± 1.3 5.6 ± 1.4 5.5 ± 1.2 .285
pCO2 categories
<4.67 110 (18.4) 53 (18.0) 17 (16.3)
4.67 to <6.4 202 (33.8) 114 (38.6) 44 (42.3) .362
≥6.4 86 (14.4) 58 (19.7) 25 (24.0)
Missing 199 (33.3) 70 (23.7) 18 (17.3)
HCO3-	(mmol/l) 24.9 ± 4.4 24.3 ± 4.8 23.8 ± 5.6 .105
HCO3-	categories
<22 88 (14.7) 65 (22.0) 25 (24.0)
22 to <29 252 (42.2) 130 (44.1) 47 (45.2) .251
≥29 54 (9.0) 27 (9.2) 14 (13.5)
Missing 203 (34.0) 73 (24.7) 18 (17.3)
pH 7.41 ± 0.07 7.38 ± 0.07 7.37 ± 0.10 <.001
pH categories
<7.30 23 (3.9) 22 (7.5) 14 (13.5)
7.30 to <7.35 35 (5.9) 35 (11.9) 12 (11.5) .001
7.35 to <7.45 233 (39.0) 128 (43.4) 45 (43.3)
≥7.45 103 (17.3) 37 (12.5) 15 (14.4)
Missing 203 (34.0) 73 (24.7) 18 (17.3)
Urea (mmol/l) 6.2	(4.3	–	10.5) 7.2	(5.0	–	12.4) 12.9	(8.2	–	19.9) 0
Urea categories
<7.8 361 (60.5) 155 (52.5) 20 (19.2) <.001
≥7.8 208 (34.8) 128 (43.4) 80 (76.9)
Missing 28 (4.7) 12 (4.1) 4 (3.8)
Potassium	(K+,	mmol/l) 4.1 ± 0.5 4.3 ± 0.7 4.6 ± 0.8 <.001
K categories
2.5 to <5.3 518 (86.8) 239 (81.0) 73 (70.2) <.001
≥5.3 13 (2.2) 19 (6.4) 14 (13.5)
Missing 66 (11.1) 37 (12.5) 17 (16.3)
Sodium	(Na+,	mmol/l) 138.7 ± 6.5 137.2 ± 6.7 136.9 ± 6.8 .001
Na categories
<133 62 (10.4) 58 (19.7) 14 (13.5) .002
133 to <145 435 (72.9) 199 (67.5) 79 (76.0)
≥145 72 (12.1) 26 (8.8) 7 (6.7)
Missing 28 (4.7) 12 (4.1) 4 (3.8)
eGFR	(ml/min/1.73m2) 73	(47	–	90) 63	(39	–	88) 22	(8	–	47) 0
eGFR	categories
<30 77 (12.9) 55 (18.6) 57 (54.8)
30 to <60 119 (19.9) 72 (24.4) 24 (23.1) <.001
(Continues)
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reason,	we	were	unable	to	analyse	results	and	outcomes	between	
those	 with	 type	 1	 and	 2	 diabetes.	 Secondly,	 the	 results	 reflect	
the findings in people who attended the hospital but does not ac-
count	for	COVID-	19	cases	treated	in	the	community	setting	only.	
Furthermore,	 some	 variables	 had	 missing	 data,	 but	 to	 minimize	
the	 impact	 of	 this	 on	 the	 results,	 missing	 data	 categories	 were	
used in the multivariable analysis. We were unable to account for 
some variables including use of medications for diabetes or hyper-
tension.	Also	it	was	not	possible	to	account	for	people	with	pre-	
diabetes	in	this	study.	Finally,	data	regarding	HbA1c	and	diabetes	
Non- diabetes DM- NC DM+C p*
≥60 372 (62.3) 156 (52.9) 18 (17.3)
Missing 29 (4.9) 12 (4.1) 5 (4.8)
Lymphocytes	(x	109/L) 1.0	(0.7	–	1.3) 0.9	(0.6	–	1.4) 0.8	(0.6	–	1.0) .006
Lymphocytes	categories
<1.5 465 (77.9) 220 (74.6) 89 (85.6) .052
≥1.5 103 (17.3) 64 (21.7) 12 (11.5)
Missing 29 (4.9) 11 (3.7) 3 (2.9)
CRP	(mg/L) 99	(41	–	168) 113.5	(55.5	–	192.8) 89	(43	–	137) .023
CRP	categories
<10 47 (7.9) 19 (6.4) 6 (5.8)
10 to < 100 233 (39.0) 104 (35.3) 50 (48.1) .139
≥100 277 (46.4) 153 (51.9) 41 (39.4)
Missing 40 (6.7) 19 (6.4) 7 (6.7)
Albumin	(g/L) 30.2 ± 6.1 29.0 ± 6.0 28.1 ± 6.3 .001
Albumin	categories
<25 95 (15.9) 62 (21.0) 26 (25.0)
25 to < 35 326 (54.6) 167 (56.6) 55 (52.9) .07
≥35 130 (21.8) 50 (16.9) 17 (16.3)
Missing 46 (7.7) 16 (5.4) 6 (5.8)
Temperature (Celsius) 36.9 ± 1.0 37.0 ± 1.2 36.7 ± 1.2 .031
Temperature categories
<37.8 489 (81.9) 218 (73.9) 84 (80.8) .022
≥37.8 107 (17.9) 76 (25.8) 20 (19.2)
Missing 1 (0.2) 1 (0.3) 0 (0.0)
Heart rate (beats/min) 91.3 ± 19.6 94.2 ± 19.9 86.5 ± 19.0 .002
Heart rate categories
<80 161 (27.0) 69 (23.4) 39 (37.5)
80 to <100 267 (44.7) 114 (38.6) 44 (42.3) .002
≥100 168 (28.1) 111 (37.6) 21 (20.2)
Missing 1 (0.2) 1 (0.3) 0 (0.0)
pO2	(kPa) 6.4	(3.9	–	9.5) 6.9	(4.1	–	9.8) 5.5	(3.7	–	8.3) .209
pO2 categories
<7.3 234 (39.2) 117 (39.7) 57 (54.8)
7.3 to <10 74 (12.4) 53 (18.0) 11 (10.6) .147
≥10 90 (15.1) 54 (18.3) 18 (17.3)




used for median comparison.
Abbreviations:	CRP,	C-	reactive	protein;	eGFR,	estimated	glomerular	filtration	rate;	HCO3-	,	bicarbonate;	pCO2,	partial	pressure	of	carbon	dioxide.
TA B L E  2 (Continued)
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duration	were	 not	 available	 in	 our	 analysis,	 although	 those	with	
complications	are	likely	to	have	higher	HbA1c	and	longer	diabetes	
duration.
The	 strengths	 of	 this	 study	 include	 the	 in-	depth	 phenotyping	
which was made possible with the presence of the appropriate data 
management	systems	in	the	hospital	trust.	Also,	cases	of	COVID-	19	
were	 laboratory	 confirmed.	 In	 addition,	 our	 study	 population	 in-




as	 one	 parameter	 for	 scoring,	 without	 considering	 presence/	
F I G U R E  1 Measures	of	metabolic	acidosis,	I	inflammation	and	immune	response	after	hospital	admission.	Data	presented	for	mean	or	
median	values	over	time.	Key:	HCO3,	bicarbonate	level;	pCO2,	partial	pressure	of	carbon	dioxide;	K,	potassium	level;	CRP,	C-	reactive	protein	
level;	Na,	sodium	level;	Ur,	urea	level;	pO2,	partial	pressure	of	oxygen
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In	 this	multi-	ethnic	 cohort	of	 adults	with	COVID-	19	presenting	 to	
hospitals,	we	found	clinical	and	biochemical	profiles	were	adverse	in	
people	with	DM+C.
F I G U R E  2 Renal	function,	electrolytes,	and	physiological	and	laboratory	measurements	after	hospital	admission.	Data	presented	for	
mean	or	median	values	over	time.	Key:	HCO3,	bicarbonate	level;	pCO2,	partial	pressure	of	carbon	dioxide;	K,	potassium	level;	CRP,	C-	reactive	
protein	level;	Na,	sodium	level;	Ur,	urea	level;	pO2,	partial	pressure	of	oxygen
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